20241216_INAF_Ringkasan Risalah//Risalah RUPS_31829445_lamp3.pdf

     The Company also uploaded Meeting Agenda                  Materials   on   the   Company's     website
     (https://www.indofarma.id) 20 November 2024.

D. There are no additional proposals for Meeting Agenda from the Company's Shareholders until the
   deadline as specified in Article 23 paragraph 6 letter a of the Company's Articles of Association, namely
   until 7 (seven) days before the date of the Invitation to the Meeting which is announced on
   20 November 2024.

E. The meeting was attended by all members of the Board of Commissioners, members of the Board of
   Directors and Shareholders of the Company, namely:

     Board of Commissioners:
     Acting President Commissioner                        : Dr. DIDI AGUS MINTADI;
     Independent Commissioner                             : TEDDY WIBISANA;

     Board of Directors:
     President Director                                   : YELIANDRIANI;
     Director of Operational                              : Drs. ANDI PRAZOS.

     as well as Shareholders and proxies of Shareholder representatives both physically and electronically
     present via eASY.KSEI, who in total own 2.500.035.000 shares including Series A Dwiwarna shares or
     representing 80,6653508 % of the total shares with valid voting rights that have been issued by the
     Company until the day the Meeting is held, namely 3,099,267,500 shares consisting of:
     - 1 Series A Dwiwarna share; And
     - 3,099,267,499 Series B shares
     taking into account the List of Company Shareholders as of 19 November 2024 until 16.00 West
     Indonesia Time.

F. The Meeting was chaired by the Acting President Commissioner of the Company, Dr. DIDI AGUS
   MINTADI, as per the Board of Commissioners’ letter dated 11 November 2024 Number S-44/DK-
   INAF/XI/2024.

G. The Meeting was held with a single agenda item as follows:
   Approval of the Plan to Sell Company Assets which constitute more than 50% of the Company's Total
   Net Worth.

H. During the Meeting, a presentation on the general condition of the Company was delivered by the
   Company's Commissioner, namely Dr. DIDI AGUS MINTADI.

I.   In the Single Agenda for the Meeting, the opportunity was given to shareholders and proxies of
     shareholders of the Company who were present physically or electronically to ask questions and/or
     opinions. On the Single Agenda for the Meeting, there were no shareholders and proxies of the
     Company's shareholders present physically or electronically who asked questions and/or opinions

J.   That the decision-making mechanism at the Meeting is carried out by deliberation to reach consensus
     in accordance with Article 40 taking into account Article 28 POJK No. 15/2020. In the event that
     deliberation to reach a consensus is not reached, the decision is taken by voting. The voting mechanism
     is carried out openly, calculated from votes legally cast at the Meeting and through eASY.KSEI.

                                                      2

That at the Meeting a decision was taken as stated in the deed “Minutes of the Extraordinary General
Meeting of Shareholders of PT INDONESIA FARMA Tbk abbreviated as PT INDOFARMA Tbk” dated 12
December 2024 Number 07 which the minutes of the deed were made by the Notary Utiek Rochmuliati
Abdurachman, SH., MLI, MKn., which are basically as follows:

In the Single Agenda of the Meeting:
Of all shares with valid voting rights who were present and/or represented either physically or
electronically at the Meeting, there were no Disapproval votes; amounting to 2,600 shares or
0.0001040% voting Abstain; while the remaining 2,500,032,400 shares or 99.9998960%, including 1
(one) Series A Dwiwarna share, voted Agree.

In accordance with the provisions of the Meeting Rules and Regulations, Shareholders who do not vote
(abstain) are deemed to have cast the same vote as the majority of Shareholders who cast votes.

Thus: The Meeting with a unanimous vote based on deliberation to reach consensus, namely
2,500,035,000 shares or 100% of the total votes cast at the Meeting decided:

1. Approved the transfer of Company assets through sales which constitute more than 50% of the
   Company's total net assets for company needs which will be carried out in the form of sales of
   company assets in the form of land and buildings which are non-collateral assets and non-
   production collateral assets with the following details:
   a. Non-Collateral Assets
       1) Empty factory in the Delta Silicon Industrial Area, Lemah Abang, Cibatu, Kab. Bekasi;
       2) Vacant land on Jl. Sriwijaya, Jakasampurna, West Bekasi;
       3) Residential houses in the Citra Raya Housing Complex, Cikupa, Tangerang with 5 SHGB;
       4) Vacant land on Jl. W. Monginsidi, Kupang City-Teluk Betung Utara, Lampung;
       5) Empty warehouse on Jl. Ali Gatmir No. 37, Ilir Timur 1 District, Palembang City with 5 SHGB;
       6) Empty warehouse on Jl. Sultan Taha No. 5, Pasar Jambi Village, Jambi Province;
       7) Vacant land on Jl. Hj. Adam Malik No. 126, West Medan District, Medan;
       8) Branch office at Crown Hill Estate Housing Complex, Batam City District, Batam City;
       9) Branch office on Jl. Rahadi Husman No. 6, West Pontianak District, Pontianak City;
       10) Branch office on Jl. Sutomo No. 39, Sawerigading Village, Makassar City;
   b. Non-Production Collateral Assets
       Land and buildings on Jalan Tambak No. 2, Kebon Manggis, Matraman, East Jakarta.
2. Give authority to the Board of Directors to take all necessary actions in connection with sales that
   constitute more than 50% of the Company's total net assets, while still paying attention to
   applicable regulations, including provisions in the capital market sector and agreements with third
   parties.


                                     Jakarta, 16 December 2024
                                  Board of Directors of the Company




                                                 3